Emergent BioSolutions | EBS - Interest Expense On Debt


Emergent BioSolutions reported $17.9M in Interest Expense on Debt for its fiscal quarter ending in March of 2023.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Akebia Therapeutics 364.15M 18.56M Sep/2025
ALKERMES USD 12.28M 7.63M Dec/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amarin USD 3K 5K Dec/2024
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Coherus Biosciences USD 2.15M 3.2M Mar/2025
Exact Sciences USD 9.79M 46K Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Heron Therapeutics USD 500K 900K Sep/2024
Ionis Pharmaceuticals USD 18M 0 Dec/2025
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Lexicon Pharmaceuticals USD 2.21M 2.74M Jun/2024
Lonza CHF 84M 14M Jun/2025
Merck USD 412M 85M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Myriad Genetics USD 800K 100K Mar/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pacira USD 3.89M 387K Dec/2025
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Sanofi EUR -25M 252M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025
Xoma USD 3.4M 150K Jun/2024